Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21983452 | 0.79 | ALDH1A1 (0.35) | HSD17B10ALDH1A1BCL2L1MCL1 | |
| SCHEMBL16612057 | 0.74 | ACHE (0.45) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20126954 | 0.71 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL18889225 | 0.71 | KDM4E (0.50) | ALDH1A1MAPTBCL2L1MCL1 | |
| SCHEMBL9826992 | 0.71 | HSD17B10 (0.37) | HSD17B10CYP1A2CYP2A6SMN1; SMN2 | |
| SCHEMBL9827000 | 0.70 | GAA (0.33) | HSD17B10RAPGEF4MAPT | |
| SCHEMBL15281129 | 0.70 | ALDH1A1 (0.39) | HSD17B10ALDH1A1 | |
| SCHEMBL806604 | 0.70 | PLAU (0.55) | HSD17B10CYP1A2CYP2A6ALDH1A1MAPT | |
| SCHEMBL4416724 | 0.69 | ALDH1A1 (0.52) | HSD17B10CYP2A6ALDH1A1MAPT | |
| SCHEMBL25809514 | 0.68 | MAPT (0.41) | HSD17B10ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110227407-B | Modified boron carbide nitrogen material and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-9382265-B2 | Oxazolidone compound, preparing method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | CYP3A43, CYP2C9, F2 | HSD17B10 451/4885CYP1A2 14/4885CYP2A6 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.